ICB - From Start To Success

We find and validate the right target for your indication

We have extensive experience in target identification and validation across a broad spectrum of therapeutic indications. We use state of the art technologies, including bioinformatics, RNAi, CrispR gene editing, chemical probes along with profiling of clinical sample collections for target expression in relevant cell types which are available to help support your project.

We identify the right molecules for your drug discovery program

Access to a world-class HTS screening library containing three million well characterized compounds that can be  screened in tailor-made assay setups at high throughput (up to 750.000 data points per day). In addition, we apply high-throughput crystallography and biophysical methods to screen for fragments and use structure determination to enable the fragment-to-lead process.

Using our experience in the generation of lead compounds we pave the way from hit to lead

Broad experience in the generation of early lead compounds, from initial hit series, for testing in biochemical and cellular assays facilitates the quick validation of the target hypothesis and paves the way for in vivo lead compounds.

Your lead series will be further optimized to examine the efficacy in in vivo animal models

Further refinement of each early lead series, with respect to potency, selectivity and PK properties, enables investigation of their efficacy in in vivo animal models

We move your early lead series forward to in vivo testing

We offer comprehensive capabilities to enable human clinical trials, such as human efficacious dose prediction, identification of  pharmacodynamic biomarkers and PK drivers for efficacy etc. for a broad spectrum of indications.

We identify the most suited indication to develop your asset

We identify Biomarkers from pharmacodynamic markers enabling PK/PD studies to predictive biomarkers for indication profiling and patient selection.

Long term experience in identification of PoC indications and validation pharmacodynamic as well as disease models, selection of pharmacodynamic biomarkers for PK/PD studies, identification of efficacy drivers, supporting clinical dose prediction and proving relevant exposure levels in early clinical studies. Use of predictive biomarkers, also called stratification biomarkers, for indication profiling and early definition patient selection startegies. Platform technologies such as immunohistochemistry, in situ hybridisation, flow cytometry, ELISA/MSD and RT-PCR are in routine use.